Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors

血管生成抑制剂的抗肿瘤作用依次增强；贝伐单抗，索拉非尼和沙利度胺。除索拉非尼和沙利度胺外，双药组的抗肿瘤效果均低于单药组。然而，由于双疗法的数量不足以考虑它们，因此需要更多关于双疗法的研究。当确定血管生成抑制剂的抗肿瘤作用时，最好和简单的方法是使用CT测量治疗前后肿瘤大小的变化。用CT / DSA测量增强比的变化，病理评价肿瘤坏死率和肿瘤血管数量不适合评价血管生成抑制剂的疗效。

The anti-tumor effect of the angiogenesis inhibitors increased in the following order; bevacizumab, sorafenib, and thalidomide. The anti-tumor effects of the dual therapies except sorafenib and thalidomide were lower than those of the single therapies. However, the numbers of the dual therapies were not enough to consider them, therefore, more studies about the dual therapies were necessary. When the anti-tumor effect of the angiogenesis inhibitor was determined, the best and simple way was to measure the change of the tumor sizes before and after the therapy using CT. To measure the change of enhancement ratio using CT / DSA and to evaluate the necrosis ratio and the numbers of tumor vessels pathologically were unfitted for the response evaluation of the angiogenesis inhibitors.